Citigroup Inc Prelude Therapeutics Inc Transaction History

Citigroup Inc

$169 Billion
Q3 2024

A detailed history of Citigroup Inc transactions in Prelude Therapeutics Inc stock. As of the latest transaction made, Citigroup Inc holds 9,655 shares of PRLD stock, worth $11,296. This represents 0.0% of its overall portfolio holdings.

Number of Shares

9,655

Previous 3,014 220.34%

Holding current value

$11,296

Previous $11,000 72.73%

% of portfolio

0.0%

Previous 0.0%

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 12, 2024	BUY	$2.07 - $6.37 $13,746 - $42,303	6,641 Added 220.34%	9,655 $19,000
Q2 2024 Aug 12, 2024	BUY	$3.32 - $5.63 $680 - $1,154	205 Added 7.3%	3,014 $11,000
Q1 2024 May 10, 2024	BUY	$2.68 - $4.84 $1,827 - $3,300	682 Added 32.06%	2,809 $13,000
Q4 2023 Feb 09, 2024	BUY	$1.69 - $4.37 $2,705 - $6,996	1,601 Added 304.37%	2,127 $9,000
Q3 2023 Nov 09, 2023	SELL	$2.74 - $4.79 $9,083 - $15,878	-3,315 Reduced 86.31%	526 $1,000
Q2 2023 Aug 10, 2023	SELL	$4.45 - $8.12 $297,820 - $543,439	-66,926 Reduced 94.57%	3,841 $17,000
Q1 2023 May 11, 2023	BUY	$4.58 - $7.34 $48,983 - $78,501	10,695 Added 17.8%	70,767 $403,000
Q4 2022 Feb 09, 2023	BUY	$4.61 - $8.5 $237,599 - $438,090	51,540 Added 604.08%	60,072 $362,000
Q3 2022 Nov 10, 2022	BUY	$5.0 - $8.82 $38,455 - $67,834	7,691 Added 914.51%	8,532 $56,000
Q2 2022 Aug 10, 2022	SELL	$4.0 - $7.55 $3,512 - $6,628	-878 Reduced 51.08%	841 $4,000
Q1 2022 May 12, 2022	SELL	$6.9 - $13.22 $16,277 - $31,185	-2,359 Reduced 57.85%	1,719 $12,000
Q4 2021 Feb 10, 2022	SELL	$11.89 - $31.74 $240,059 - $640,830	-20,190 Reduced 83.2%	4,078 $51,000
Q3 2021 Nov 10, 2021	BUY	$25.78 - $38.65 $625,629 - $937,958	24,268 New	24,268 $758,000

Others Institutions Holding PRLD

# of Institutions

Shares Held

35.9M

Call Options Held

500

Put Options Held

300

View Full List

About Prelude Therapeutics Inc

Ticker PRLD
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 36,369,200
Market Cap $42.6M
Description
Prelude Therapeutics Incorporated, a clinical-stage precision oncology company, focuses on the discovery and development of novel precision cancer medicines to underserved patients. It is developing PRT543 that is in Phase 1 clinical trials in select solid tumors and myeloid malignancies; and PRT811, which is in Phase 1 clinical trials in solid ...

More about PRLD

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Citigroup Inc, based on Form 13F filings with the SEC.

News

Stay updated on Citigroup Inc with notifications on news.

Account